These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 20630698)

  • 1. Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance.
    Zuo Q; Shi M; Li L; Chen J; Luo R
    Biomed Pharmacother; 2010 Oct; 64(8):550-8. PubMed ID: 20630698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship between the insulin-like growth factor 1 receptor signaling pathway and the resistance of nasopharyngeal carcinoma to cetuximab].
    Zuo Q; Luo RC
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):575-9. PubMed ID: 21122407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of silencing H-ras gene by RNA interference on cetuximab-sensitivity of cetuximab-resistant human nasopharyngeal carcinoma cells].
    Zuo Q; Luo RC
    Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):574-8. PubMed ID: 22325215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation between ras gene and the resistance of nasopharyngeal carcinoma to cetuximab].
    Zuo Q; Luo RC
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1415-7. PubMed ID: 20584693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Ras signaling pathway mediates cetuximab resistance in nasopharyngeal carcinoma.
    Zuo Q; Shi M; Chen J; Liao W
    Biomed Pharmacother; 2011 Jun; 65(3):168-74. PubMed ID: 21602020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
    Kim SM; Kim JS; Kim JH; Yun CO; Kim EM; Kim HK; Solca F; Choi SY; Cho BC
    Cancer Lett; 2010 Oct; 296(2):150-9. PubMed ID: 20444542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
    Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
    Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
    Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
    Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Marchal S; Galenne T; Juin P; Becuwe P; Merlin JL
    Cancer Gene Ther; 2009 Jun; 16(6):498-507. PubMed ID: 19165235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells.
    Saki M; Toulany M; Rodemann HP
    Radiother Oncol; 2013 Sep; 108(3):473-8. PubMed ID: 23891090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear Klf4 accumulation is associated with cetuximab drug-resistance and predicts poor prognosis of nasopharyngeal carcinoma.
    Li X; Zhao Z; Yi S; Ma L; Li M; Liu M; Zhang Y; Liu G
    J Transl Med; 2018 Jul; 16(1):183. PubMed ID: 29973197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
    Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
    Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
    Yamasaki F; Johansen MJ; Zhang D; Krishnamurthy S; Felix E; Bartholomeusz C; Aguilar RJ; Kurisu K; Mills GB; Hortobagyi GN; Ueno NT
    Cancer Res; 2007 Jun; 67(12):5779-88. PubMed ID: 17575145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
    Feng YH; Tsao CJ; Wu CL; Chang JG; Lu PJ; Yeh KT; Shieh GS; Shiau AL; Lee JC
    Cancer Sci; 2010 Sep; 101(9):2033-8. PubMed ID: 20624167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells.
    Yuan YL; Zhou XH; Song J; Qiu XP; Li J; Ye LF
    J Laryngol Otol; 2008 Sep; 122(9):952-60. PubMed ID: 17908353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
    Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoproteomics study of cetuximab in nasopharyngeal carcinoma.
    Sung FL; Pang RT; Ma BB; Lee MM; Chow SM; Poon TC; Chan AT
    J Proteome Res; 2006 Dec; 5(12):3260-7. PubMed ID: 17137327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.